| 证券代码：688331 | 证券简称：荣昌生物 公告编号：2023-030 | | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | 荣昌生物制药（烟台）股份有限公司 第二届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）第二届监事会第四 次会议于 2023 年 11 月 3 日在公司会议室以现场方式召开，会议已于 2023 年 10 月 26 日以通讯方式发出会议通知。会议应出席监事 3 名，实际出席监事 3 名， 会议由监事会主席任广科先生主持，会议的召集、召开、表决程序符合《中华人 民共和国公司法》（以下简称"《公司法》"）和《荣昌生物制药（烟台）股份有 限公司章程》（以下简称"《公司章程》"）的相关规定，所作决议合法有效。经与 会监事表决，会议形成如下决议： 二、监事会会议审议情况 （一）审议通过《关于向公司 2022 年 A 股限制性股票激励计划激励对象授 予预留部分限制性股票的议 ...

《荣昌生物制药（烟台）股份有限公司 2022 年 A 股限制性股票激励计划》 （以下简称"《2022 年激励计划》"）规定的公司 2022 年 A 股限制性股票激励计 划（以下简称"本次激励计划"）预留授予条件已经成就，根据荣昌生物制药（烟 台）股份有限公司（以下简称"公司"）2022 年第二次临时股东大会、2022 年第 一次 A 股类别股东大会及 2022 年第一次 H 股类别股东大会的授权，公司于 2023 年 11 月 3 日召开的第二届董事会第七次会议、第二届监事会第四次会议，审议 通过了《关于向 2022 年 A 股限制性股票激励计划激励对象预留授予限制性股票 的议案》，确定 2023 年 11 月 3 日为预留授予日，以 36.36 元/股的授予价格向 16 名激励对象授予 71.055 万股限制性股票。现将有关事项说明如下： 一、本次激励计划授予情况 （一）本次激励计划预留授予已履行的决策程序和信息披露情况 1、2022 年 10 月 16 日，公司召开第一届董事会第二十四次会议，会议审议 通过了《关于<荣昌生物制药（烟台）股份有限公司 2022 年 A 股限制性股票激 限制性股票预留授予日： ...

注 3:上表中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 荣昌生物制药（烟台）股份有限公司董事会 2023 年 11 月 3 日 | | 序 | | | A 类权 | B 类权益 | 本次获授 的限制性 | 占授予限 制性股票 | 占本激励计 划预留授予 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 姓名 号 | 国籍 | 职务 | 益（万 股） | （万股） | 股票数量 | 总数的比 | 日公司股本 | | | | | | | | （万股） | 例 | 总额的比例 | | 一、董事、高级管理人员、核心技术人员（1 | | | | | 人） | | | | | | 1 温庆凯 | 中国 | 董事会秘书 | 0 | 2.055 | 2.055 | 0.57% | 0.0038% | | | | 合计 | | 0 | 2.055 | 2.055 | 0.57% | 0.0038% | | | 二、其他激励对象 | | | | | | | | | | （15 | 董事会认为需要激励的其他员工 | | 0 | ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2023-029 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 第二届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 特此公告。 荣昌生物制药（烟台）股份有限公司董事会 二、董事会会议审议情况 （一）审议通过《关于向公司 2022 年 A 股限制性股票激励计划激励对象授 予预留部分限制性股票的议案》 根据《上市公司股权激励管理办法》、《荣昌生物制药（烟台）股份有限公 司 2022 年 A 股限制性股票激励计划》及其摘要的相关规定和公司 2022 年第二 次临时股东大会、2022 年第一次 A 股类别股东大会及 2022 年第一次 H 股类别 股东大会的授权，董事会认为公司 2022 年 A 股限制性股票激励计划规定的预留 授予条件已经成就，同意确定以 2023 年 11 月 3 日为预留授予日，授予价格为 36.36 元 ...

关于荣昌生物制药（烟台）股份有限公司 向 2022 年 A 股限制性股票激励计划激励对象 授予预留部分限制性股票的法律意见书 中国·北京 二〇二三年十一月 法律意见书 法律意见书 北京海润天睿律师事务所 对本所出具的本法律意见书，本所律师声明如下： 1、本所律师承诺依据本法律意见书出具日以前已经发生或存在的事实和我 国现行法律法规及中国证监会及相关主管机构、部门的有关规定发表法律意见。 2、本所已严格履行法定职责，遵循了勤勉尽责和诚实信用原则，对本次激 励计划的合法、合规、真实、有效性进行了核实验证，法律意见书中不存在虚 假记载、误导性陈述或者重大遗漏。 3、本所同意将本法律意见书作为荣昌生物本次激励计划所必备的法律文件， 并依法对出具的法律意见承担相应的法律责任。本法律意见书仅供荣昌生物为 本次激励计划之目的使用，未经本所同意，不得用作任何其他目的。 4、本所仅就与荣昌生物本次激励计划有关的法律事项发表法律意见，有关 其他专业事项依赖于其他专业机构出具的意见。 1 北京海润天睿律师事务所 关于荣昌生物制药（烟台）股份有限公司 向 2022 年 A 股限制性股票激励计划激励对象 授予预留部分限制性股票的法律意 ...

1、公司本次激励计划预留授予的激励对象均不存在《管理办法》第八条规 定的不得成为激励对象的情形: (1) 最近 12个月内被证券交易所认定为不适当人选; 荣昌生物制药(烟台)股份有限公司 监事会关于 2022年 A 股限制性股票激励计划 预留授予激励对象名单的核查意见(截止预留授予日) 荣昌生物制药(烟台)股份有限公司(以下简称"公司")监事会根据《中华 人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下 简称"《证券法》")、《上市公司股权激励管理办法》(以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》(以下简称"《上市规则》")、《科创板上 市公司自律监管指南第 4 号 -- 股权激励信息披露》(以下简称"《自律监管指 南》")等相关法律、法规及规范性文件和《荣昌生物制药(烟台)股份有限公司 章程》(以下简称"《公司章程》")的有关规定,对公司 2022年A股限制性股票 激励计划(以下简称"本次激励计划")预留授予的激励对象名单进行审核,发表 核查意见如下: 3、公司预留授予的激励对象人员名单与公司 2022 年第二次临时股东大会、 2022 年第一次 A 股类 ...

Financial Overview - Revenue for Q3 2023 reached approximately CNY 350 million, representing a year-on-year growth of about 58% [2] - Sales expenses for Q3 2023 were approximately CNY 190 million, a year-on-year increase of about 48%, with a sales expense ratio of 55%, significantly down from 82% in the previous half [2] - R&D expenses for Q3 2023 amounted to CNY 320 million, reflecting a year-on-year growth of about 49% due to increased clinical spending both domestically and internationally [3] - Capital expenditures for Q3 2023 were approximately CNY 280 million, primarily invested in the construction of the Yantai headquarters, equipment purchases, and land acquisition for the Shanghai R&D center [3] R&D Pipeline Progress - RC18 in China: - SLE: Complete application materials submitted to CDE at the end of 2022; clinical trials for pediatric SLE and lupus nephritis are ongoing [3] - RA: Phase III clinical trial completed, meeting primary clinical endpoints; application materials submitted to CDE in August [3] - MG/pSS/IgAN: Phase III clinical trials progressing smoothly [3] - Exploring potential for RC18 in new treatment areas such as IgG4-RD and membranous nephritis [3] - RC18 International: - SLE: Phase III international multi-center clinical trials are underway [3] - MG: Received orphan drug designation from FDA; Phase III clinical trial initiated [3] - RC48 in China: - Focus on multiple clinical studies for urothelial carcinoma [4] - Ongoing clinical trials for gastric cancer and breast cancer [4] - Approved clinical research for gynecological tumors [4] Commercial Product Sales Progress - Sales of Taitasip showed rapid growth in Q3 2023 [5] - As of September 30, 2023, approximately 700 personnel, including over 100 in nephrology and about 50 in internal medicine [5] - Coverage expanded to over 2,300 hospitals nationwide, with 150 new hospitals added this quarter [5] - Over 23,000 target doctors covered [5] - Sales of Vidisizumab remained stable in Q3 2023 [5] - Approximately 600 personnel as of September 30, 2023 [5] - Coverage extended to about 2,000 hospitals, with over 630 hospitals admitted [5] - Coverage of over 24,000 target doctors [5]

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥347 million, representing a year-on-year increase of 58.28%[4] - The net profit attributable to shareholders for Q3 2023 was approximately -¥327 million, with a year-to-date net profit of approximately -¥1.03 billion[4] - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase from RMB 569,635,902.97 in the same period of 2022, representing a growth of approximately 35%[19] - The total operating revenue for Q3 2023 was approximately $769.47 million, an increase from $569.64 million in Q3 2022, representing a growth of 35%[20] - The net profit for Q3 2023 was a loss of approximately $1.03 billion, worsening from a loss of $688.22 million in Q3 2022[20] - The total comprehensive income for Q3 2023 was approximately a loss of $1.04 billion, compared to a loss of $680.11 million in Q3 2022[21] Research and Development - R&D expenses for Q3 2023 totaled approximately ¥318 million, an increase of 49.16% compared to the same period last year[5] - The proportion of R&D expenses to operating revenue was 91.49% for Q3 2023, a decrease of 5.59 percentage points year-on-year[5] - Research and development expenses reached approximately $857.98 million in Q3 2023, compared to $662.54 million in Q3 2022, reflecting a 29.5% increase[20] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately ¥5.51 billion, a decrease of 8.42% from the end of the previous year[5] - As of September 30, 2023, total current assets amounted to RMB 2,235,196,172.88, down from RMB 3,212,137,039.58 at the end of 2022, indicating a decrease of about 30%[16] - The company's total assets decreased to RMB 5,514,357,338.62 from RMB 6,021,189,680.87, reflecting a decline of about 8%[18] - Total liabilities as of September 30, 2023, were RMB 1,558,115,861.03, compared to RMB 1,040,890,051.43 at the end of 2022, indicating an increase of approximately 50%[18] - The company reported a decrease in total equity attributable to shareholders to RMB 3,956,241,477.59 from RMB 4,980,299,629.44, a decline of about 20%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,045[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling approximately 189.57 million shares[11] Cash Flow - The cash flow from operating activities for the first three quarters of 2023 was negative at approximately $1.11 billion, compared to a negative cash flow of $1.08 billion in the same period of 2022[22] - Cash inflow from investment activities in Q3 2023 totaled approximately $846.96 million, an increase from $685.65 million in Q3 2022[23] - The net cash flow from financing activities in Q3 2023 was approximately $511.63 million, a significant decrease from $2.44 billion in Q3 2022[23] - The ending cash and cash equivalents balance for Q3 2023 was approximately $546.09 million, down from $1.97 billion at the end of Q3 2022[23] Earnings Per Share - The company reported a basic and diluted earnings per share of -¥0.61 for Q3 2023[5] - Basic and diluted earnings per share for Q3 2023 were both -1.91 yuan, compared to -1.32 yuan in Q3 2022[21]

Financial Performance - The company's operating revenue for Q3 2023 was approximately CNY 347.04 million, representing a year-on-year increase of 58.28%[6]. - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 327.23 million, with a cumulative loss of CNY 1.03 billion for the year-to-date[6]. - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase of 35% compared to RMB 569,635,902.97 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was a loss of RMB 1,030,585,859.60, worsening from a loss of RMB 688,219,233.92 in the same period of 2022[21]. - The company experienced a total comprehensive loss of RMB 1,038,494,630.57 in 2023, compared to a loss of RMB 680,108,752.02 in 2022[22]. Research and Development - Research and development expenses totaled CNY 317.52 million in Q3 2023, an increase of 49.16% compared to the same period last year[7]. - The ratio of R&D expenses to operating revenue was 91.49%, a decrease of 5.59 percentage points year-on-year[7]. - The company continues to invest heavily in R&D to support its drug pipeline and clinical trials, leading to increased operational costs[12]. - Research and development expenses increased to RMB 857,977,852.40 in 2023, compared to RMB 662,541,383.59 in 2022, marking a 29.5% rise[21]. Assets and Liabilities - Total assets at the end of Q3 2023 were approximately CNY 5.51 billion, down 8.42% from the end of the previous year[7]. - The equity attributable to shareholders decreased by 20.56% year-on-year, amounting to approximately CNY 3.96 billion[7]. - The company's total assets as of September 30, 2023, amount to ¥5,514,357,338.62, a decrease from ¥6,021,189,680.87 at the end of 2022[19]. - Current assets total ¥2,235,196,172.88, down from ¥3,212,137,039.58 in the previous year[18]. - The total liabilities as of September 30, 2023, are ¥1,558,115,861.03, compared to ¥1,040,890,051.43 in the previous year[19]. Cash Flow - The company reported a net cash flow from operating activities of CNY -1.11 billion for the year-to-date[7]. - Cash flow from operating activities showed a net outflow of RMB 1,114,762,180.68 in 2023, compared to a net outflow of RMB 1,080,292,854.28 in 2022[23]. - Cash inflow from investment activities totaled RMB 846,955,292.55 in 2023, while cash outflow was RMB 1,767,323,954.74, resulting in a net outflow of RMB 920,368,662.19[24]. - The company reported cash and cash equivalents at the end of Q3 2023 amounting to RMB 546,094,957.35, down from RMB 1,967,108,319.61 at the end of Q3 2022[24]. - The company has a total of ¥609,013,239.33 in cash and cash equivalents, down from ¥2,187,326,306.04[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,045[13]. - HKSCC NOMINEES LIMITED holds 189,566,228 shares, accounting for 34.83% of total shares[14]. Market Strategy - The increase in operating revenue was primarily driven by higher sales of injectable drugs, including TaiTasi and VidiXimab[11]. - The company is focusing on expanding its market presence and developing new products and technologies[16].